Roche’s lung cancer gamble flames out as TIGIT digits come up short in phase 3news2022-03-30T09:10:41+00:00March 30th, 2022|FierceBiotech|
Karyopharm hoping for some Keytruda stardust as former Merck & Co. exec joins as CMOnews2022-03-29T17:27:45+00:00March 29th, 2022|FierceBiotech|
Outgoing NIAID vaccine R&D chief John Mascola reflects on leading ‘NASA-type incubator’news2022-03-29T15:45:41+00:00March 29th, 2022|FierceBiotech|
Cuts to the Bone: Orthopedic biotech slashes C-suite, overhauls entire pipelinenews2022-03-29T14:26:47+00:00March 29th, 2022|FierceBiotech|
Neuron23 snags $100M and a new Parkinson’s disease candidatenews2022-03-29T14:19:51+00:00March 29th, 2022|FierceBiotech|
ImmunoGen files ovarian cancer ADC with FDA, a week after scaring investors with iffy survival datanews2022-03-29T13:34:39+00:00March 29th, 2022|FierceBiotech|
Pfizer’s $7B ulcerative colitis drug racks up another phase 3 win, laying the groundwork for approval filingsnews2022-03-29T12:08:14+00:00March 29th, 2022|FierceBiotech|
Sanofi pulls IGM into dealmaking whirlwind, paying $150M upfront to form 6-target R&D pactnews2022-03-29T09:58:52+00:00March 29th, 2022|FierceBiotech|
Biden seeks $2.1B funding boost for FDA, part of pan-agency pandemic preparedness plannews2022-03-28T18:26:24+00:00March 28th, 2022|FierceBiotech|
Amylyx to answer for single-study ALS application at FDA advisory panelnews2022-03-28T14:47:13+00:00March 28th, 2022|FierceBiotech|
